Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
28 Dec 2023
28 Dec 2023
Historique:
received:
03
07
2023
accepted:
22
11
2023
medline:
28
12
2023
pubmed:
28
12
2023
entrez:
28
12
2023
Statut:
aheadofprint
Résumé
Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed. A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR-146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83-0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes. We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.
Sections du résumé
BACKGROUND
BACKGROUND
Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.
OBJECTIVE
OBJECTIVE
To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.
METHODS
METHODS
We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.
RESULTS
RESULTS
A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR-146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83-0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.
CONCLUSION
CONCLUSIONS
We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI01583
Organisme : Fondo Europeo de Desarrollo Regional
Organisme : Novartis
Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102-113.
Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.
Galluzzo M, Talamonti M, De Simone C, D'Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18:727-735.
Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36:1796-1804.
Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184:50-59.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera Acosta E, Vidal D, Vilarrasa E, et al. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: multicenter study in 384 Spanish patients. Dermatol Ther. 2022;35(12):e15929.
Daudén E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, Villarasa E, et al. Multicenter retrospective study of Secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain. Dermatol Ther (Heidelb). 2021;11:2207-2215.
Tavakolpour S, Darvishi M, Ghasemiadl M. Pharmacogenetics: a strategy for personalized medicine for autoimmune diseases. Clin Genet. 2018;93:481-497.
Berna-Rico E, Perez-Bootello J, Abbad-Jaime de Aragon C, Gonzalez-Cantero A. Genetic influence on treatment response in psoriasis: new insights into personalized medicine. Int J Mol Sci. 2023;24:9850.
Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179:1072-1080.
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol. 2019;181:413-414.
van Vugt LJ, van den Reek JMPA, Meulewaeter E, Hakobjan M, Heddes N, Traks T, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34:112-118.
Morelli M, Galluzzo M, Madonna S, Scarponi C, Scaglione GL, Galluccio T, et al. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opin Biol Ther. 2021;21(2):259-270.
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists biologics and Immunomodulators register, BADBIR). Br J Dermatol. 2020;182:1158-1166.
De Maturana EL, Ye Y, Calle ML, Rothman N, Urrea V, Kogevinas M, et al. Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. PLoS One. 2013;8(12):e83745.
Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A tutorial on conducting genome-wide association studies: quality control and statistical analysis. Int J Methods Psychiatr Res. 2018;27:27(2).
Anzengruber F, Drach M, Maul JT, Kolios AG, Meier B, Navarini AA. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series. J Eur Acad Dermatol Venereol. 2018;32:e274-e276.
Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, et al. Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Hum Mol Genet. 2017;26:4301-4313.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945-1960.
Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
Löfgren SE, Frostegård J, Truedsson L, Pons-Estel BA, D'Alfonso S, Witte T, et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 2012;13:268-274.
Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Belmonte C, Cabaleiro T, Román M, et al. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017;18:631-638.
Jiménez Morales A, Maldonado-Montoro M, Martínez de la Plata JE, Pérez Ramírez C, Daddaoua A, Alarcón Payer C, et al. FCGR2A/FCGR3A gene polymorphisms and clinical variables as predictors of response to Tocilizumab and rituximab in patients with rheumatoid arthritis. J Clin Pharmacol. 2019;59:517-531.
Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, et al. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics J. 2018;18:70-75.
Capon F, Bijlmakers MJ, Wolf N, Quaranta M, Huffmeier U, Allen M, et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet. 2008;17:1938-1945.
Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E. Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol. 2018;19:209-222.
Muromoto R, Hirao T, Tawa K, Hirashima K, Kon S, Kitai Y, et al. IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes. Int Immunol. 2016;28(9):443-452.
Ferreira MAR, Hottenga JJ, Warrington NM, Medland SE, Willemsen G, Lawrence RW, et al. Sequence variants in three loci influence monocyte counts and erythrocyte volume. Am J Hum Genet. 2009;85:745-749.
Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Franziska Degenhardt 30,31, Andreas J Forstner 30,31, Andrea Hofmann 30,31, the international IBD genetics consortium (IIBDGC) 32, international genetics of ankylosing spondylitis consortium (IGAS) 32, international PSC study group (IPSCSG) 32, Gene Konstantinos. N Lazaridis. 2016;17:510-518.
Posadas-Sánchez R, Pérez-Hernández N, Rodríguez-Pérez JM, Coral-Vázquez RM, Roque-Ramírez B, Llorente L, et al. Interleukin-27 polymorphisms are associated with premature coronary artery disease and metabolic parameters in the Mexican population: the genetics of atherosclerotic disease (GEA) Mexican study. Oncotarget. 2017;8:64459-64470.
Gottlieb AB, Merola JF, Chen R, Levi E, Duffin KC. Assessing clinical response and defining minimal disease activity in plaque psoriasis with the physician global assessment and body surface area (PGA × BSA) composite tool: an analysis of apremilast phase 3 ESTEEM data. J Am Acad Dermatol. 2017;77:1178-1180.
Gold LS, Hansen JB, Patel D, Veverka KA, Strober B. PGAxBSA composite versus PASI: comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. J Am Acad Dermatol. 2020;83:131-138.